Genetic test aims to improve breast cancer decisions for black and hispanic women
NCT ID NCT05755269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding a polygenic risk score (a genetic test) to standard breast cancer risk tools helps African American and Hispanic women make better decisions about screening and prevention. Researchers enrolled 19 women at higher risk for breast cancer. The study was terminated early, so findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that personalized genetic risk information helps minority women choose better breast cancer screening and prevention.
- What could go wrong
- The study was terminated early with only 19 participants, so results are limited and may not apply broadly. It was a small, early-stage feasibility study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
19 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
African American/Black or Hispanic/Latinx women attending the Mayo Clinic Breast Center.
- Ages
-
30 to 75 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women who self-identify as African American/Black or Hispanic/Latinx * Women \>= 30 years old and =\< 75 years old * Women with any of the following: * IBIS (Tyrer-Cuzik) score of \>= 5% for the 10 year risk OR * BCRAT (Gail Model) score of \> 3 % for the 5 year risk * History of biopsy proven atypical ductal hyperplasia or atypical lobular hyperplasia (with risk calculator assessment A and B) * History of biopsy proven lobular carcinoma in situ (with risk calculator assessment A and B) * Able to participate in all aspects of the study * Understand and signed the study informed consent Exclusion Criteria: * Women whose calculated risk for breast cancer falls below the threshold * Unable to give informed consent * Prior history of invasive breast cancer, ductal carcinoma in situ or other breast cancers * Women who are pregnant or breastfeeding * Prior use of prevention drugs for longer than 6 months * Prior risk reducing or prophylactic mastectomy * Known pathogenic genetic mutation linked to breast cancer (such as BRCA 1/2, PALB2, ATM, CHEK2)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast atypical ductal hyperplasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Green dye vs blue dye: which finds Cancer-Linked lymph nodes better?
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- Can exercise and nutrition prehab help breast cancer patients through chemo?
- Can a clotting drug cut mastectomy wound drainage?
- A simple dye might replace radioactive tracers in cancer staging
- Can new tracers make many cancers light up on scans?